Literature DB >> 6320489

Some properties of the human platelet vasopressin receptor.

M E Thomas, A H Osmani, M C Scrutton.   

Abstract

Aggregation of human platelets by vasopressin is potently inhibited by 1-[beta mercapto-(beta, beta'-cyclopentamethylene propionic acid)]-L-arginine vasopressin, a selective vasopressor (V1) antagonist. 1-Desamino-8-D-arginine-vasopressin, a selective anti-diuretic (V2) agonist failed to induce aggregation and acted as a weak antagonist. Vasopressin analogues which lacked the N-terminal amino group or which contained an uncharged amino acid residue at position 8 acted as partial agonists for the human platelet. The response to such partial agonists could be enhanced by increasing the cytosolic Ca2+ concentration but not by altering the level of cyclic-3', 5'-AMP. These observations provide further evidence indicating that the platelet vasopressin receptor is of the V1 sub-type.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6320489     DOI: 10.1016/0049-3848(83)90057-9

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  4 in total

1.  Characterization of human platelet vasopressin receptors.

Authors:  M Thibonnier; J M Roberts
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

2.  Nature and properties of human platelet vasopressin receptors.

Authors:  D Vittet; A Rondot; B Cantau; J M Launay; C Chevillard
Journal:  Biochem J       Date:  1986-02-01       Impact factor: 3.857

3.  Activation of V1-receptors by vasopressin stimulates inositol phospholipid hydrolysis and arachidonate metabolism in human platelets.

Authors:  W Siess; M Stifel; H Binder; P C Weber
Journal:  Biochem J       Date:  1986-01-01       Impact factor: 3.857

4.  Evidence for intact V1-vasopressin receptors in congenital nephrogenic diabetes insipidus.

Authors:  N Knoers; P M Janssens; J Goertz; L A Monnens
Journal:  Eur J Pediatr       Date:  1992-05       Impact factor: 3.183

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.